Literature DB >> 29373727

Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis.

Emilio J Laserna-Mendieta1,2, Adam G Clooney1,2, Julián F Carretero-Gomez3, Carthage Moran1,4, Donal Sheehan1,4, James A Nolan1,2, Colin Hill1,2, Cormac G M Gahan1,2,5, Susan A Joyce1,6, Fergus Shanahan1,4, Marcus J Claesson1,2.   

Abstract

BACKGROUND AND AIMS: Alterations in short chain fatty acid metabolism, particularly butyrate, have been reported in inflammatory bowel disease, but results have been conflicting because of small study numbers and failure to distinguish disease type, activity or other variables such as diet. We performed a comparative assessment of the capacity of the microbiota for butyrate synthesis, by quantifying butyryl-CoA:acetate CoA-transferase [BCoAT] gene content in stool from patients with Crohn's disease [CD; n = 71], ulcerative colitis [UC; n = 58] and controls [n = 75], and determined whether it was related to active vs inactive inflammation, microbial diversity, and composition and/or dietary habits.
METHODS: BCoAT gene content was quantified by quantitative polymerase chain reaction [qPCR]. Disease activity was assessed clinically and faecal calprotectin concentration measured. Microbial composition was determined by sequencing 16S rRNA gene. Dietary data were collected using an established food frequency questionnaire.
RESULTS: Reduced butyrate-synthetic capacity was found in patients with active and inactive CD [p < 0.001 and p < 0.01, respectively], but only in active UC [p < 0.05]. In CD, low BCoAT gene content was associated with ileal location, stenotic behaviour, increased inflammation, lower microbial diversity, greater microbiota compositional change, and decreased butyrogenic taxa. Reduced BCoAT gene content in patients with CD was linked with a different regimen characterised by lower dietary fibre.
CONCLUSIONS: Reduced butyrate-synthetic capacity of the microbiota is more evident in CD than UC and may relate to reduced fibre intake. The results suggest that simple replacement of butyrate per se may be therapeutically inadequate, whereas manipulation of microbial synthesis, perhaps by dietary means, may be more appropriate.
Copyright © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  Butyrate synthesis; inflammatory bowel disease; microbiota

Mesh:

Substances:

Year:  2018        PMID: 29373727     DOI: 10.1093/ecco-jcc/jjx137

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  22 in total

Review 1.  Dietary Fiber and Gastrointestinal Disease: an Evolving Story.

Authors:  John O'Grady; Fergus Shanahan
Journal:  Curr Gastroenterol Rep       Date:  2018-11-08

2.  Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms.

Authors:  Xiaohua Pan; Xin Fang; Fei Wang; Hongli Li; Wenying Niu; Wenjie Liang; Chengfei Wu; Jiahong Li; Xing Tu; Li-Long Pan; Jia Sun
Journal:  Br J Pharmacol       Date:  2019-12-08       Impact factor: 8.739

3.  Fecal microbiota and metabolites are distinct in a pilot study of pediatric Crohn's disease patients with higher levels of perceived stress.

Authors:  Laura M Mackner; Emmanuel Hatzakis; Jacob M Allen; Ronald H Davies; Sandra C Kim; Ross M Maltz; Michael T Bailey
Journal:  Psychoneuroendocrinology       Date:  2019-10-03       Impact factor: 4.905

Review 4.  Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease.

Authors:  Laila Aldars-García; María Chaparro; Javier P Gisbert
Journal:  Microorganisms       Date:  2021-04-30

Review 5.  MAP, Johne's disease and the microbiome; current knowledge and future considerations.

Authors:  Chloe Matthews; Paul D Cotter; Jim O' Mahony
Journal:  Anim Microbiome       Date:  2021-05-07

Review 6.  Towards a deeper understanding of microbial communities: integrating experimental data with dynamic models.

Authors:  Yili Qian; Freeman Lan; Ophelia S Venturelli
Journal:  Curr Opin Microbiol       Date:  2021-06-04       Impact factor: 7.584

7.  Intestinal changes associated with fluoride exposure in rats: Integrative morphological, proteomic and microbiome analyses.

Authors:  Aline Dionizio; Dawud Abduweli Uyghurturk; Carina Guimarães Souza Melo; Isabela Tomazini Sabino-Arias; Tamara Teodoro Araujo; Talita Mendes Silva Ventura; Juliana Vanessa Colombo Martins Perles; Jacqueline Nelisis Zanoni; Pamela Den Besten; Marília Afonso Rabelo Buzalaf
Journal:  Chemosphere       Date:  2021-01-11       Impact factor: 8.943

8.  Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties.

Authors:  Bruk Getachew; Joseph I Aubee; Richard S Schottenfeld; Antonei B Csoka; Karl M Thompson; Yousef Tizabi
Journal:  BMC Microbiol       Date:  2018-12-22       Impact factor: 3.605

9.  Inflammation in gastrointestinal disorders: prevalent socioeconomic factors.

Authors:  Davide Giuseppe Ribaldone; Rinaldo Pellicano; Giovanni Clemente Actis
Journal:  Clin Exp Gastroenterol       Date:  2019-07-19

10.  Effects of C-Terminal Domain of the Heavy Chain of Tetanus Toxin on Gut Microbiota in a Rat Model of Depression.

Authors:  Bruk Getachew; Yousef Tizabi
Journal:  Clin Pharmacol Transl Med       Date:  2019-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.